FDA_Warning_Letters, Import_Alerts_&_EU_Non-Compliances_in_2019
X

Find Drugs for Cardiology/Vascular Diseases in Phase II Clinical Development in UNITED STATES

A collaboration with SCORR Marketing

Loading...

All Data

Filters Filter refresh
×
FILTER DATA :
News Type filter
    Company filter
      Product Type filter
        Deal Size filter
          Upfront Payment filter
            refresh

            Product Type

            Companies

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Levosimendan

            Therapeutic Area: Cardiology/Vascular Diseases

            Highest Development Status: Phase II Product Type: Small molecule

            Partner/Sponsor/Collaborator: H.C. Wainwright & Co

            Deal Size: $2.8 million Upfront Cash: Undisclosed

            Deal Type: Public Offering March 12, 2020

            Details:

            Tenax currently intends to use the net proceeds from the offering to further its clinical trials of levosimendan, for research and development and general corporate purposes.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): CK-3773274

            Therapeutic Area: Cardiology/Vascular Diseases

            Highest Development Status: Phase II Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable February 20, 2020

            Details:

            Preclinical studies demonstrate distinct binding site for Next-Generation Cardiac Myosin Inhibitor.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Sodium Nitrite

            Therapeutic Area: Cardiology/Vascular Diseases

            Highest Development Status: Phase II Product Type: Small molecule

            Partner/Sponsor/Collaborator: JanOne

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Agreement February 06, 2020

            Details:

            JanOne’s lead drug clinical candidate TV1001SR to treat PAD and associated pain will be manufactured by CoreRX Pharma with phase 2b trials expected to begin Q4 2020.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): AKCEA-ANGPTL3-LRx

            Therapeutic Area: Cardiology/Vascular Diseases

            Highest Development Status: Phase II Product Type: Large molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable January 28, 2020

            Details:

            Primary and multiple secondary endpoints were met with significant reduction in triglyceride levels, additional lipid parameters and ANGPTL3.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): AKCEA-APOCIII-LRx

            Therapeutic Area: Cardiology/Vascular Diseases

            Highest Development Status: Phase II Product Type: Large molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable January 22, 2020

            Details:

            AKCEA-APOCIII-L Rx demonstrate favorable safety and tolerability were in hypertriglyceridemia patients in the study.